autoimmune response cells start attacking gut adrenaline glands normal tissue t cells active concern says chan suggests instead team t cells site tumor specialized attacking cancer deng says lung cancer tumors targeted trial not easily accessible says team reassured fda approved antibody therapies not high rate autoimmune response phase trial designed foremost test approach safe examine effects different dosage regimens people deng says team plans proceed slowly increasing dosage gradually starting patient monitored closely effects researchers closely watch markers blood indicate treatment working lu says review process took half year required team invest lot time human resources including close communication